Abstract
Research Overview
Partnering with Radiopharmaceutical Companies Likely to Take the Edge off the Need for Constant Innovation
Divided into gamma camera and positron emission tomography (PET) scanner markets, nuclear medicine imaging is one of the most sought after technologies to diagnose diseases. The maturing nuclear medicine imaging systems market in Europe, however, needs to be revived through innovations that attract customers. The best response to this constant pressure is likely to be partnering with radiopharmaceutical companies as well as offering complete and comprehensive solutions to customers.
This Frost & Sullivan research service provides country-specific analysis of new strategies in the European nuclear medicine imaging systems markets. It also includes valuable information on current and future technology trends, while presenting market revenues, industry challenges and strategic recommendations to counter them. In addition, this study offers an analysis of the industry's competitive structure and presents valuable strategies to maintain in the markets.
Innovations and Improvement in Quality of Care Drive the Nuclear Medicine Imaging Market
"The drive towards improving detection capabilities and patient care is expected to lead to advanced techniques being introduced in this market," says the analyst of this study. "An example would be the fusion of gamma camera and computed tomography (CT) scanners that provide anatomical as well as functional advantages to physicians."
Factors such as technological advancements are further aiding this market by creating early replacements. Single photon emitted computed tomography (SPECT)-CT scanners are expected to be increasingly adopted, thus driving the gamma camera market, whereas the availability of fluorodeoxyglucose (FDG) is likely to add to PET scanners' increased sales in the future. The increasing use of nuclear medicine imaging systems in hospitals and physician offices has led to heightened demand for these systems. The growing use is further expected to be fuelled by the development of new imaging agents.